

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GENENT.073A2  APPLICANT ERICKSON et al.  FILING DATE March 16, 2001	APPLICATION NO. 09/811,123  GROUP 1614
--	---	--

SHEET 1 OF 2  
 RECEIVED  
 SEP 06 2001  
 TECH CENTER 1600/2900

OIP  
 SEP 04 2001  
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
AH	1	4,450,254	05/22/84	Isley et al.	524	399	06/25/82

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
AH	2 ✓ Arteaga, C.L. et al., "p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair," <u>Cancer Research</u> , Vol. 54, pp. 3758-3765 (1994).
AH	3 ✓ Bacus, S.S. et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells," <u>Cancer Research</u> , Vol. 52, pp. 2580-2589 (1992).
AH	4 ✓ Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product," <u>Cancer Research</u> , Vol. 50, 1550-1558 (1990).
AH	5 ✓ Hancock, M.C. et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines," Vol. 51, pp. 4575-4580 (1991).
AH	6 ✓ Issell, B.F. et al., "Maytansine," <u>Cancer Treatment Reviews</u> , Vol. 5, pp. 199-207 (1978).

EXAMINER <u>Anne L. Halleran</u>	DATE CONSIDERED <u>10/21/02</u>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

TECH CENTER 1600/2900

RECEIVED

SEP 06 2001



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A23	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT ERICKSON et al.	
		FILING DATE March 16, 2001	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
ALH	7	Kasprzyk, P.G. et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies," <u>Cancer Research</u> , Vol. 52, pp. 2771-2776 (1992).
ALH	8	Kem, J.A. et al., "p185 <sup>neu</sup> Expression in Human Lung Adenocarcinomas Predicts Shortened Survival," <u>Cancer Research</u> , Vol. 50, pp. 5184-5191 (1990).
ALH	9	Lewis, G.D. et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness," <u>Cancer Research</u> , Vol. 56, pp. 1457-1465 (1996).
ALH	10	Maier, L.A. et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/ <i>neu</i> Gene Product c-erbB-2," <u>Cancer Research</u> , Vol. 51, pp. 5361-5369 (1991).
ALH	11	Park, Joo-Bae et al., "Amplification, Overexpression, and Rearrangement of the <i>erbB-2</i> Protooncogene in Primary Human Stomach Carcinomas," <u>Cancer Research</u> , Vol. 49, pp. 6605-6609 (1989).
ALH	12	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SKREPNIK, NEBOJSA ET AL: "Effects of anti-erbB -2 (HER-2/ <i>neu</i> ) recombinant oncotoxin Ar209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice" retrieved from STN Database accession no. 126:14452 XP002164007, abstract & CLIN. CANCER RES. (1996), 2(11), 1851-1857.
ALH	13	Sarup, J.C. et al., "Characterization of an Anti-p185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth," <u>Growth Regulation</u> , Vol. 1, pp. 72-82 (1991).
ALH	14	Shawver, L.K. et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells," <u>Cancer Research</u> , Vol. 54, pp. 1367-1373 (1994).
ALH	15	Skrepnik, N. et al., "Effects of Anti-erbB2 (HER-2/ <i>neu</i> ) Recombinant Oncotoxin AR209 on Human Non-Small Cell Lung Carcinoma Grown Orthotopically in Athymic Nude Mice," <u>Clinical Cancer Research</u> , Vol. 2, pp. 1851-1857 (1996).
ALH	16	Yipetta, E.S. et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy," <u>Cancer Research</u> , Vol. 54, pp. 5301-5309 (1994).
ALH	17	Weiner, D.B. et al., "Expression of the <i>neu</i> Gene-encoded Protein (P185 <sup>neu</sup> ) in Human Non-Small Cell Carcinomas of the Lung," <u>Cancer Research</u> , Vol. 50, pp. 421-425 (1990).
ALH	18	Yokota, J. et al., "Amplification of c-erbB2 Oncogene in Human Adenocarcinomas in Vivo," <u>The Lancet</u> , Vol. 1, pp. 765-767 (1986).
ALH	19	Yonemura, Y. et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer," <u>Cancer Research</u> , Vol. 51, pp. 1034-1038 (1991).

W:\DOCS\ANM\ANM-2033.DOC  
082201

EXAMINER	Anne L. Holleran	DATE CONSIDERED	10/21/02
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.073A2APPLICATION NO.  
09/811,123

RECEIVED

AUG 09 2001

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
ERICKSON et alFILING DATE  
March 16, 2001GROUP  
1614

TELEPHONE 500/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
ALH	1	3,896,111	07/22/75	Kupchan et al.	260	239.3 T	02/20/73
	2	4,137,230	01/30/79	Hashimoto et al.	260	239.3 P	03/15/78
	3	4,151,042	04/24/79	Higashide et al.	195	96	06/29/77
	4	4,248,870	02/03/81	Miyashita et al.	424	248.54	10/18/79
	5	4,256,746	03/17/81	Miyashita et al.	424	248.54	11/09/79
	6	4,260,608	04/07/81	Miyashita et al.	424	248.54	11/09/79
	7	4,265,814	05/05/81	Hashimoto et al.	260	239.3 P	03/19/79
	8	4,294,757	10/13/81	Asai	260	239.3 P	01/15/80
	9	4,307,016	12/22/81	Asai et al.	260	239.3 P	05/27/80
	10	4,308,268	12/29/81	Miyashita et al.	424	248.54	05/28/80
	11	4,308,269	12/29/81	Miyashita et al.	424	248.54	06/06/80
	12	4,309,428	01/05/82	Miyashita et al.	424	248.54	07/23/80
	13	4,313,946	02/02/82	Powell et al.	424	248.54	01/27/81
	14	4,315,929	02/16/82	Freedman et al.	424	248.54	01/27/81
	15	4,317,821	03/02/82	Miyashita et al.	424	248.54	05/22/80
	16	4,322,348	03/30/82	Asai et al.	260	239.3 P	05/14/80
	17	4,331,598	05/25/82	Hasegawa et al.	260	239.3 P	09/17/80
	18	4,361,650	11/30/82	Asai et al.	435	119	08/07/81
	19	4,362,663	12/07/82	Kida et al.	260	239.3 P	09/17/80
	20	4,364,866	12/21/82	Asai et al.	260	239.3 P	09/17/80
	21	4,371,533	02/01/83	Akimoto et al.	424	248.54	09/29/81
	22	4,424,219	01/03/84	Hashimoto et al.	424	248.54	05/03/82
	23	4,968,603	11/06/90	Slamon et al.	435	6	12/31/86
	24	5,183,884	02/02/93	Kraus et al.	536	23.5	12/01/89
	25	5,208,020	05/04/93	Chari et al.	424	85.91	07/13/92
	26	5,416,064	05/16/95	Chari et al.	514	229.5	12/07/92

EXAMINER

Anne L. Holleran

DATE CONSIDERED

10/21/02

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.073A2APPLICATION NO.  
09/811,123INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
ERICKSON et alFILING DATE  
March 16, 2001GROUP  
1614

(USE SEVERAL SHEETS IF NECESSARY)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
Alt	27	5,480,968	01/02/96	Kraus et al.	530	326	11/10/92
	28	5,677,171	10/14/97	Hudziak et al.	435	240.27	08/05/94
	29	5,772,997	06/30/98	Hudziak et al.	424	130.1	05/23/95
	30	5,783,186	07/21/98	Arakawa et al.	424	143.1	12/05/95
	31	5,821,337	10/13/98	Carter et al.	530	387.3	08/21/92
	32	5,824,311	10/20/98	Green et al.	424	138.1	11/30/94
	33	5,837,234	11/17/98	Gentile et al.	424	93.7	06/07/95
	34	5,840,525	11/24/98	Vandlen et al.	435	69.1	05/31/95
	35	5,968,517	10/19/99	Duncan et al.	424	195.1	05/22/97

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	36	<del>0.425-235-A2</del>	<del>02.05.91</del>	<del>EPO</del>				
	37	<del>WO 89/06692</del>	<del>27.07.89</del>	<del>PCT</del>				
	38	<del>WO 93/21319</del>	<del>28.10.93</del>	<del>PCT</del>				
	39	<del>WO 94/22478</del>	<del>13.10.94</del>	<del>PCT</del>				
	40	<del>WO 94/00136</del>	<del>06.01.94</del>	<del>PCT</del>				
	41	<del>WO 96/16173</del>	<del>30.05.96</del>	<del>PCT</del>				
	42	<del>WO 97/00271</del>	<del>03.01.97</del>	<del>PCT</del>				
	43	<del>WO 97/04801</del>	<del>13.02.97</del>	<del>PCT</del>				
	44	<del>WO 98/02463</del>	<del>22.01.98</del>	<del>PCT</del>				
	45	<del>WO 98/17797</del>	<del>30.04.98</del>	<del>PCT</del>				
	46	<del>WO 99/31140</del>	<del>24.06.99</del>	<del>PCT</del>				
	47	<del>WO 00/20579</del>	<del>13.04.00</del>	<del>PCT</del>				
	48	<del>WO 00/69460</del>	<del>23.11.00</del>	<del>PCT</del>				
	49	<del>WO 01/00238 A1</del>	<del>04.01.01</del>	<del>PCT</del>				
	50	<del>WO 01/00244 A2</del>	<del>04.01.01</del>	<del>PCT</del>				

EXAMINER

DATE CONSIDERED

10/21/02

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.073A2APPLICATION NO.  
09/811,123INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
ERICKSON et alFILING DATE  
March 16, 2001GROUP  
1614

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	51	WO-01/45730-A1	08-03-01	PCT				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

52	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB," <i>Br. J. Cancer</i> , Vol. 57, pp. 358-363 (1988).
53	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen," <i>Molecular Carcinogenesis</i> , Vol. 3, pp. 350-362 (1990).
54	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," <i>J. Clin. Oncol.</i> , Vol. 14, pp. 737-744 (1996).
55	Borst et al., "Oncogene Alterations in Endometrial Carcinoma," <i>Gynecol. Oncol.</i> , Vol. 38, pp. 364-366 (1990).
56	Carter et al., "Humanization of anti-p185HER2 antibody for human cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 4285-4289 (1992).
57	Chari et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs," <i>Cancer Research</i> , Vol. 52, pp. 127-131 (1992).
58	Cobleigh et al., "Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease," <i>J. Clin. Oncol.</i> , Vol. 17, pp. 2639-2648 (1999).
59	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185 <sup>neu</sup> ) in normal and transformed epithelial tissues of the digestive tract," <i>Oncogene</i> , Vol. 4, pp. 81-88 (1989).
60	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects <i>in vivo</i> ," <i>Oncogene</i> , Vol. 2, pp. 273-277 (1988).
61	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies," <i>Cell</i> , Vol. 41, pp. 695-706 (1985).
62	D'Souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 7202-7206 (1994).
63	Guérin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis," <i>Oncogene Research</i> , Vol. 3, pp. 21-31 (1988).
64	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia," <i>Cancer Letters</i> , Vol. 99, pp. 185-189 (1996).
65	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists," <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 21, pp. 15160-15167 (1992).
66	Hudziak et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor," <i>Molecular and Cellular Biology</i> , Vol. 9, No. 3, pp. 1165-1172 (1989).
67	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors," <i>Oncogene</i> , Vol. 14, pp. 2099-2109 (1997).
68	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB / epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86, pp. 9193-9197 (1989).
69	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells," <i>Molecular and Cellular Biology</i> , Vol. 11, No. 2, pp. 979-986 (1991).
70	Lewis et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies," <i>Cancer Immunol. Immunother.</i> , Vol. 37, pp. 255-263 (1993).
71	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors," <i>Cancer</i> , Vol. 65, pp. 88-92 (1990).
72	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185," <i>Oncogene</i> , Vol. 4, pp. 543-548 (1989).
73	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185 <sup>neu</sup> ," <i>Methods in enzymology</i> , Vol. 198, pp. 277-290 (1991).

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GENENT.073A2APPLICATION NO  
09/811,123INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
ERICKSON et alGROUP  
1614FILING DATE  
March 16, 2001

USE SEVERAL SHEETS IF NECESSARY)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER  
INITIAL

- 74 Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells," *Oncogene*, Vol. 9, pp. 1829-1838 (1994).
- 75 Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/P180ERBB4," *Letters to Nature*, Vol. 366, pp. 473-475 (1993).
- 76 Plowman et al., "Ligand-specific activation of HER4/p180 erbB4, a fourth member of the epidermal growth factor receptor family," *Proc. Natl. Acad. Sci. USA*, Vol. 90, pp. 1746-1750 (1993).
- 77 Liu et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," *Proc. Natl. Acad. Sci. USA*, Vol. 93, pp. 8618-8623 (1996).
- 78 Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma," *Cancer*, Vol. 79, pp. 2162-2170 (1997).
- 79 Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence In Situ Hybridization," *Human Pathology*, Vol. 28, No. 7, pp. 827-833 (1997).
- 80 Sadasivan et al., "Overexpression of HER-2/NEU May be an Indicator of Poor Prognosis in Prostate Cancer," *The Journal of Urology*, Vol. 150, pp. 126-131 (1993).
- 81 Schaefer et al., "y-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175," *Oncogene*, Vol. 15, pp. 1385-1394 (1997).
- 82 Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells," *The Journal of Biological Chemistry*, Vol. 266, No. 22, pp. 14300-14305 (1991).
- 83 Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," *Journal of clinical Immunology*, Vol. 11, No. 3 (1991).
- 84 Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," *Science*, Vol. 235, pp. 177-182 (1987).
- 85 Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," *Science*, Vol. 244, pp. 707-712 (1989).
- 86 Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin," *The Journal of Biological Chemistry*, Vol. 269, No. 20, pp. 14661-14665 (1994).
- 87 Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," *Proc. Natl. Acad. Sci. USA*, Vol. 88, pp. 8691-8695 (1991).
- 88 Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells with HER2/NEU Gene Amplification," *Int. J. Cancer*, Vol. 47, pp. 933-937 (1991).
- 89 Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas," *Pathobiology*, Vol. 59, pp. 46-52 (1991).
- 90 Xu et al., "Antibody-Induced Growth Inhibition is Mediated Through Immunochemically and Functionally Distinct Epitopes on the Extracellular Domain of c-erbB-2 (HER-2/neu) Gene Product," Vol. 53, pp. 401-408 (1993).
- 91 Zhou et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer," *Molecular Carcinogenesis*, Vol. 3, pp. 254-261 (1990).
- 92 King et al., "Amplification of a Novel y-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line," *Science*, Vol. 229, pp. 974-976 (1985).
- 93 Fukushige et al., "Localization of a Novel y-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line," *Molecular and Cellular Biology*, Vol. 6, No. 3, pp. 955-958 (1986).
- 94 DATABASE CHEMABS: Online; CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRECHBIEL, MARTIN W. ET AL.: "Synthesis and evaluation of antiproliferative activity of a geldanamycin-herceptin immunoconjugate." Retrieved from STN Database accession no. 2000:796068, XP002164006, abstract & ABSTR. PAP. - AM. CHEM. SOC. (2000), 220TH, MEDI-071.

W:\DOCS\GRD\GRD-5817.DOC  
062201

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.